OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology-Neuroimmunology & Neuroinflammation is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes	323
Guillain-Barré syndrome related to COVID-19 infection	270
Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease	184
COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia	156
Acute disseminated encephalomyelitis after SARS-CoV-2 infection	152
COVID-19 outcomes in MS	128
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology	120
Neurologic syndromes related to anti-GAD65	106
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID	106
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome	106
COVID-19-associated acute necrotizing myelitis	99
COVID-19 and MS disease-modifying therapies	85
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	85
Guillain-Barré syndrome related to SARS-CoV-2 infection	82
Neurosarcoidosis	79
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes	74
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France	73
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders	72
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	68
COVID-19 Among Patients With Multiple Sclerosis	68
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	67
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders	67
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis	67
Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies	66
Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation	65

Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2–associated encephalitis	61
Rituximab, MS, and pregnancy	60
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	60
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders	59
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease	59
COVID-19-associated ophthalmoparesis and hypothalamic involvement	58
Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies	57
Clinical significance of Kelch-like protein 11 antibodies	56
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder	55
Clinical and MRI phenotypes of sarcoidosis-associated myelopathy	55
COVID-19 Severity in Multiple Sclerosis	54
COVID-19—White matter and globus pallidum lesions	53
Presentations and mechanisms of CNS disorders related to COVID-19	53
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease	52
Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis	52
CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19	52
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis	48
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression	47
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis	46
IgG4-Mediated Neurologic Autoimmunities	46
Retinal Optical Coherence Tomography in Neuromyelitis Optica	45